Results 11 to 20 of about 12,649 (233)

Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) [PDF]

World Allergy Organization Journal, 2021
Background: There are limited real-world studies on the differences in leukotriene receptor antagonists (LTRA), H1-antihistamines (H1-AH), and inhaled corticosteroids (ICS) associated neuropsychiatric events.
Sainan Bian, Lisha Li, Zixi Wang, Le Cui, Yingyang Xu, Kai Guan, Bin Zhao, Lianglu Wang, Jia Yin   +8 more
doaj   +2 more sources

Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial [PDF]

Frontiers in Pharmacology, 2023
Background: Type 2 diabetes mellitus (T2DM) is common with obesity. Metformin is a first-line therapy for this condition. However, it has only a minor impact on weight loss in some patients.Aim: This study aimed to evaluate the effectiveness ...
Eman El-Khateeb, Eman El-Khateeb, Eman I. El-Berri, Esraa M. Mosalam, Mohamed Z. Nooh, Shimaa Abdelsattar, Amira M. Alghamdi, Sarah Alrubia, Mahmoud S. Abdallah   +8 more
doaj   +2 more sources

Effects of oral cysteine leukotriene receptor antagonist-montelukast on adenoid lymphoid tissue: a histopathological study under light microscope [PDF]

Frontiers in Pharmacology, 2023
Background: Adenoidal hypertrophy (AH) is one of the most common causes of upper airway obstruction in children. Drug and surgical treatment are the typical treatment of AH.
Zhengying Wang, Zhengying Wang, Xiuling Wu, Xiuling Wu, Jinghong Liu, Jinghong Liu, Yu Wang, Yu Wang, Yue Zhang, Yan Wu, Yingxue Kang, Yingxue Kang, Ronghai Zhang, Ronghai Zhang, Jin Li, Jin Li, Delong Liu   +16 more
doaj   +2 more sources

Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist? [PDF]

The Scientific World Journal, 2010
The prototype cysteinyl leukotriene receptor antagonist, montelukast, is generally considered to have a niche application in the therapy of exercise- and aspirin-induced asthma.
Gregory R. Tintinger, Charles Feldman, Annette J. Theron, Ronald Anderson   +3 more
doaj   +2 more sources

The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial [PDF]

BMC Cancer, 2020
Background Leukotriene receptor antagonists (LTRAs) are broadly used for the management of allergic asthma and have recently been indicated to inhibit carcinogenesis and cancer cell growth.
Takuma Higurashi, Jun Arimoto, Keiichi Ashikari, Tomohiro Takatsu, Noboru Misawa, Tsutomu Yoshihara, Tetsuya Matsuura, Akiko Fuyuki, Hidenori Ohkubo, Atsushi Nakajima   +9 more
doaj   +2 more sources

Cysteine Leukotriene Receptor Antagonist—Montelukast—Treatment Improves Experimental Abdominal Aortic Aneurysms in Mice [PDF]

Cardiovascular Therapeutics
Conclusion: Montelukast treatment improves experimental nondissected AAAs in mice partly by improving aortic inflammation.
Kexin Li, Meng Li, Panpan Wei, Kangli Tian, Haole Liu, Weilai Fu, Haiwen Hou, Yajie Chen, Baohui Xu, Yankui Li, Sihai Zhao   +10 more
doaj   +2 more sources

Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction‐associated fatty liver disease

Hepatology, EarlyView., 2022
Increased liver content of DHA‐derived small lipid autacoids (i.e resolvin D1 and maresin 1) associates with enhanced mitochondrial oxidative phosphorylation, fatty acid β‐oxidation and bioenergetic metabolic flux. These features provide hepatic protection from steatotic, pro‐inflammatory and fibrogenic insults.
Cristina López‐Vicario, David Sebastián, Mireia Casulleras, Marta Duran‐Güell, Roger Flores‐Costa, Ferran Aguilar, Juan José Lozano, Ingrid W. Zhang, Esther Titos, Jing X. Kang, Antonio Zorzano, Makoto Arita, Joan Clària   +12 more
wiley   +1 more source

Combinatorial targeting of G‐protein‐coupled bile acid receptor 1 and cysteinyl leukotriene receptor 1 reveals a mechanistic role for bile acids and leukotrienes in drug‐induced liver injury

Hepatology, EarlyView., 2022
CHIN117 is a dual cysteinyl leukotriene receptor 1 (CYSLTR1) antagonist and G‐protein‐coupled bile acid receptor 1 (GPBAR1) agonist. In the liver, GPBAR1 and CYSLTR1 are coexpressed by liver sinusoidal endothelial cells (LSECs), HSCs, circulating monocytes/macrophages, and liver resident macrophages (Kupffer cells).
Michele Biagioli, Silvia Marchianò, Cristina di Giorgio, Rosalinda Roselli, Martina Bordoni, Rachele Bellini, Bianca Fiorillo, Valentina Sepe, Bruno Catalanotti, Chiara Cassiano, Maria Chiara Monti, Eleonora Distrutti, Angela Zampella, Stefano Fiorucci   +13 more
wiley   +1 more source

Effect of montelukast on platelet activating factor- and tachykinin induced mucus secretion in the rat

Journal of Occupational Medicine and Toxicology, 2008
Background Platelet activating factor and tachykinins (substance P, neurokinin A, neurokinin B) are important mediators contributing to increased airway secretion in the context of different types of respiratory diseases including acute and chronic ...
Groneberg David A, Staats Petra, Schmidt Rene, Wagner Ulrich   +3 more
doaj   +1 more source

Leukotriene receptor antagonist therapy [PDF]

Postgraduate Medical Journal, 2000
Leukotriene receptor antagonists (LTRA) are a new class of drugs for asthma treatment, available in tablet form. Their unique mechanism of action results in a combination of both bronchodilator and anti-inflammatory effects. While their optimal place in asthma management is still under review, LTRA represent an important advance in asthma ...
openaire   +2 more sources